Antibody development company CytomX Therapeutics Inc. named biotech veteran Dr. Hoyoung Huh as chairman.
The privately held company, which moved to South San Francisco after lining up $30 million in financing in 2010, is developing monoclonal antibodies that can target specific tissues in cancer, inflammatory disease and autoimmune conditions.
No comments:
Post a Comment